| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1374773 | Bioorganic & Medicinal Chemistry Letters | 2008 | 4 Pages |
Abstract
Inhibition of Rho kinase (ROCK) is an attractive strategy for the treatment of diseases such as hypertension, glaucoma, and cancer. Here we report chroman-3-amides as highly potent ROCK inhibitors with sufficient kinase selectivity, excellent cell activity, good microsomal stability, and desirable pharmacokinetic properties for study as potential therapeutic agents.
Graphical abstractHere we report chroman-3-amides as potent ROCK inhibitors with sufficient kinase selectivity, cell permeability, stability, and desirable pharmacokinetic properties for study as potential therapeutic agents.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Yen Ting Chen, Thomas D. Bannister, Amiee Weiser, Evelyn Griffin, Li Lin, Claudia Ruiz, Michael D. Cameron, Stephan Schürer, Derek Duckett, Thomas Schröter, Philip LoGrasso, Yangbo Feng,